PeppiLibrary

Anti-aging

SS-31 peptide reference

Mitochondrial-targeted antioxidant tetrapeptide. Cardiolipin binding stabilises inner membrane.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing SS-31 notes
Default dose label40 mg
Preferred routeSubQ
Frequency label1× daily
Storage window28 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Phase 3 trials completed for multiple indications; mixed primary endpoint results

Investigational

Route map

How records are usually labeled

1 SubQ

Rotate sites for repeated dosing.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze long-term.
After mixRefrigerate 2–8 °C, use within 28 days.
Use-by cue28 days after mixing
Mixed vial window28 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 50 mg vial
Dose 40 mg
Route SubQ
Review 28d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for SS-31. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

SS-31 (elamipretide) is a synthetic 4-amino-acid peptide that selectively concentrates in mitochondrial inner membranes via electrostatic affinity for cardiolipin. It restores mitochondrial bioenergetics, scavenges reactive oxygen species at the source, and protects cristae architecture. Investigated in Phase 3 trials for primary mitochondrial myopathy, Barth syndrome, and dry age-related macular degeneration.

Also known as: Elamipretide, MTP-131, Bendavia.

Primary mitochondrial myopathy (clinical trials)Barth syndromeDry age-related macular degenerationMitochondrial-aging research

Mechanism and timing snapshot

Concentrates in mitochondrial inner membrane (1000-fold) via cardiolipin binding. Restores efficient electron transport, reduces mitochondrial ROS, and stabilises cristae. Distinct from cytosolic antioxidants — addresses ROS at production site.

Onset label60 min
Catalog onset field, when available.
Half-life label2.4 hr
~2.4 h plasma; intramitochondrial concentration sustained longer
Duration label24 hr
Catalog duration field, when available.
subQ High
topical Low
oral Low (development of oral form ongoing)

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose40 mg
Catalog dose range4 mg - 60 mg
Default routeSubQ
Frequency label1× daily
Best time labelMorning, consistent timing.
Food noteNone significant.

Catalog protocol note

40 mg subQ once daily (clinical trial dose). Lower research doses 4–10 mg also used.

Routes and site notes

Available route labelsSubQ
Preferred route labelSubQ
Common site labelsAbdomen, Thigh
Site rotation noteRotate sites for repeated dosing.

Chemistry

SequenceD-Arg-Dmt-Lys-Phe-NH2 (Dmt = 2,6-dimethyltyrosine)
Amino acids4
Molecular formulaC32H49N9O5
Molecular weight639.79 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size50 mg
DiluentBacteriostatic water
Diluent volume5 mL
Concentration note50 mg in 5 mL → 4.0 mL = 40 mg (a substantial volume; some users split into two injections).
Before reconstitutionRefrigerate 2–8 °C; freeze long-term.
After reconstitutionRefrigerate 2–8 °C, use within 28 days.
Reconstituted shelf life28 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Injection-site reactions
  • Mild headache
  • Allergic reactions

Contraindications and warnings

  • Pregnancy
  • Phase 3 trials mixed — primary endpoint failures in some studies, success in others.

Other considerations

  • Targets mitochondrial dysfunction — not a 'general antioxidant'.
  • Volume of injection at clinical dose is meaningful — split sites if needed.
  • Most validated indications are mitochondrial myopathies; healthy-aging benefits less established.

Evidence and regulatory context

Evidence levelPhase 3 trials completed for multiple indications; mixed primary endpoint results
FDA approvedNo
Regulatory statusInvestigational
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withmots-c
Avoid combining noteNot listed
Typical cycle labelongoing (clinical) or 4–8 (research)
Typical break labelPer protocol
Cycle guidanceContinuous in clinical trials; cycling for healthy-use research is empirical.

Tracking tips

  • High clinical dose (~40 mg) means meaningful injection volume — split sites if uncomfortable.
  • Targets mitochondrial dysfunction specifically — not a generic antioxidant supplement.
  • Long-term healthy-user data is sparse; most evidence is in disease populations.

References

Track it in Peppi

Keep SS-31 records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for SS-31?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use SS-31?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export SS-31 records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026